This notice is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 "Streamlined Procedures for Evaluation and Solicitation for Commercial Items," as applicable, and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested and a written solicitation document will not be issued. Submit offers on RFQ1976816. This solicitation is a request for quotes (RFQ). The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular FAC 2019-02 Effective June 5, 2019. The associated North American Industry Classification System (NAICS) code for this procurement is 541380 - Testing Laboratories. This is a total small business set aside. The National Institute of Allergy and Infectious Diseases (NIAID), Rocky Mountain Laboratories, is seeking to generate a tet-inducible knock-down of RPNP in client provided iPSC Cells. This is a request for quotes. The quotation should include the following: Cell Line Validation ASC-7102-1 1 each Pathogen Test (Human) ASC-6005 1 each Cell Transduction and Screening ASC-7102-4 1 each Screening of the selected clones by genomic PCR (20 clones) ASC-Custom-1 1 each Confirmation of the gene expression from 5 of the selected clones by RT-PCR ASC-7102-5 5 each Lentiviral Particle Purchase (Qty TBD) ASC-7102-2 1 each Expansion and cryopreservation of the top two (2) positive clones ASC-7102-6 2 each Confirmation of the gene expression from top two clones by RT-PCR after 3 passages before and after Doxycycline Induction (stability test) ASC-Custom-2 2 each Recovery test for the positive clones ASC-Custom-3 2 each iPSC Characterization by Pluripotency Marker Staining ASC-6006 2 each at Mycoplasma Test (PCR based) for the positive clones ASC-6000M 2 each Shipping S&H 1 each The prion cell biology unit requires a human induced pluripotent stem cell line with tet-inducible PrP knock-out for studies of PrP function and disease. The provider must supply the appropriate lentivirus, perform the cell transduction and screening, screen the selected clones by genomic PCR, confirm the gene expression before and after doxycycline by rt-PCR of five clones, cryopreserve positive clones, confirm gene expression by rt-PCR after 3 passages for stability, recover and characterize positive clones to ensure pluripotency and cell line integrity.*NOTE: Include ANY and ALL potential costs as line items in the quote. Submission Deadline and Point of Contact: Submission shall be received not later than July 15, 2019 1:00 p.m. MST. Offers may be e-mailed to Peggy Schott at
contact@example.gov. Place of Performance: Rocky Mountain Laboratories, 903 South 4th Street, Hamilton, MT 59840, United States Award will be based on the price, past performance, delivery, warranty, and the best value to the government. Only quotes for the above listed brand name items will be considered. PROVISIONS AND CLAUSES The government intends to award a firm, fixed price purchase order as a result of this solicitation that will included the terms and conditions set forth herein. The following additional FAR & HHSAR provisions and clauses are incorporated by reference and applicable to this requirement: The following FAR provisions apply to this acquisition: FAR 52.212-1 Instructions to Offerors Commercial Items (Oct 2018) FAR 52.212-3 Offerors Representations and Certifications - Commercial Items (Oct 2018) Offerors must complete annual representations and certifications on-line at http://www.sam.gov in accordance with FAR 52.212-3 Offerors Representations and Certifications- Commercial Items FAR 52.203-18 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements - Representation (Jan 2017) The following contract clauses apply to this acquisition: FAR 52.203-19 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements - Representation (Jan 2017) FAR 52-212-4 Contract Terms and Conditions Commercial Items (Oct 2018) FAR 52-212-5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items (May 2019) *The applicable subparagraphs of FAR52.212-5 are included in the attachment to this posting. FAR 52.232-1 Payments (Apr 1984) The following HSSAR clause applies to this acquisition: 352.222-70 Contractor Cooperation in Equal Employment Opportunity Investigations. (Dec 2015) Any responsible vendor may submit a quote which will be considered by this Agency. By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered, or in the process of registering, in the System for Award Management (SAM) database prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation (www.sam.gov). Copies of the above-referenced provisions and clauses are available from http://farsite.hill.af.mil/vmfara.htm and https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html. This is an open-market combined synopsis/solicitation for generatation of a tet-inducible knock-down of RPNP in client provided iPSC Cells as defined herein. The government intends to award a fixed-price purchase order as a result of this combined synopsis/solicitation that will include the terms and conditions set forth herein. Submission shall be received not later than July 15, 2019 by 1:00 p.m. MST. Offers may be mailed, e-mailed or faxed to Peggy Schott at
contact@example.gov or Fax to
+1 (555) 000-0000. Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f) All responsible sources may submit an offer that will be considered by this Agency. Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to Peggy Schott at
contact@example.gov.
